darusentan (HMR-4005) / Gilead 
Welcome,         Profile    Billing    Logout  

4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
darusentan (HMR-4005) / Gilead
ACTRN12606000446561: DORADO-AC – Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension

Not yet recruiting
3
800
 
Myogen, Inc., Myogen, Inc.
Resistant Hypertension
 
 
ACTRN12606000292572: DORADO – Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension

Recruiting
3
350
 
Myogen, inc.
Resistant Hypertension
 
 
ACTRN12606000310561: DORADO-EX – A Dose-Blinded, Long-Term, Safety Extension Study to the Phase 3 DORADO Study of Darusentan in Resistant Hypertension

Not yet recruiting
N/A
300
 
Myogen, Inc., Myogen, Inc.
Resistant Hypertension
 
 
ACTRN12606000447550: DORADO-AC-EX – A Double-Blind, Active-Controlled, Long-Term Safety Extension Study to the Phase 3 DORADO-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension

Not yet recruiting
N/A
700
 
Myogen, Inc., Myogen, Inc.
Resistant Hypertension
 
 

Download Options